-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Fleetwood and Lowry lift each other into Abu Dhabi lead
-
Fleetwod and Lowry lift each other into Abu Dhabi lead
-
New Zealand make changes after Barrett brothers' injuries as Scotland drop Van der Merwe
-
Dallas Cowboys' Marshawn Kneeland dies at 24: franchise
-
Pegula dispatches Paolini to keep WTA Finals semis bid alive
-
Dutch giants Ajax sack coach John Heitinga
-
Kirchner on trial in Argentina's 'biggest ever' corruption case
-
Amorim urges Man Utd to 'focus on future' after Ronaldo criticism
-
US judge drops criminal charges against Boeing over 737 MAX 8 crashes
-
World must face 'moral failure' of missing 1.5C: UN chief to COP30
-
UK grandmother leaves Indonesia death row to return home
-
Garcia broken nose adds to Barca defensive worries
-
Tight UK security ahead of match against Israeli club
-
Ethiopia's Afar region says attacked by Tigray forces
-
Nancy Pelosi, Democratic giant, Trump foe, first woman House speaker, to retire
-
Israel strikes Hezbollah targets in Lebanon
-
Burger strikes as South Africa restrict Pakistan to 269-9 in second ODI
-
Stocks slip as investors weigh earnings, tariffs
-
Police say 19 held after raid at Swedish start-up Stegra to be deported
-
Kante returns as France seek to clinch World Cup berth
-
Marcus Smith starts at full-back as England ring changes for Fiji
-
Kolisi 100th Test 'no distraction' for Erasmus' South Africa
-
Teetering Belgian government given more time to agree budget
-
Merz backs EU plan to protect steel sector from Chinese imports
-
New Zealand make Scotland changes after Barrett brothers' injuries
-
'Roy of the Rovers story' -- Farrell handed Ireland debut for Japan Test
-
Stones backs Man City team-mate Foden to pose England dilemma for Tuchel
-
Djokovic to face Alcaraz in ATP Finals groups
-
Facing climate 'overshoot', world heads into risky territory
-
Springbok skipper Kolisi to play 100th Test against France
-
Typhoon Kalmaegi hits Vietnam after killing 140 in Philippines
-
Bank of England leaves rate unchanged before UK budget
-
Germany recall Sane, hand El Mala debut for World Cup qualifers
-
India thump Australia to take 2-1 lead in T20 series
-
Cameroon's Biya, world's oldest president, sworn in for 8th term
-
Flick holding firm on Barca high line despite defensive woes
-
Battered US businesses eye improved China trade at Shanghai expo
-
France opt for Le Garrec as Dupont replacement for 'best team ever' South Africa
-
Drugmaker AstraZeneca profit jumps as US business grows
-
'Vibe coding' named word of the year by Collins dictionary
-
Vietnam evacuates thousands from coast ahead of Typhoon Kalmaegi
-
European stocks fall after gains in Asia, US
-
MotoGP legend Agostini admires Marc Marquez's 'desire to win'
-
Nepal searches for avalanche victims
-
Hezbollah rejects any negotiations between Lebanon and Israel
-
Chapman blitz leads Black Caps to tight T20 victory over West Indies
-
France urges EU to sanction Shein platform
-
France opt for Le Garrec as Dupont replacement for South Africa Test
-
Turmoil in tiaras at Miss Universe pageant in Thailand
Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
Z.AlNajjar--SF-PST